Similarities Between COVID-19 and Anti-MDA5 Syndrome: What Can We Learn for Better Care?

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2020 Jul 8

PMID 32631836

Citations 24

Authors

Margherita Giannini

Mickael Ohana

Benoit Nespola

Giovanni Zanframundo

Bernard Geny

Alain Meyer

Affiliations

Soon will be listed here.

Citing Articles

Monocyte-macrophage dynamics as key in disparate lung and peripheral immune responses in severe anti-melanoma differentiation-associated gene 5-positive dermatomyositis-related interstitial lung disease.

Shi J, Pei X, Peng J, Wu C, Lv Y, Wang X Clin Transl Med. 2025; 15(2):e70226.

PMID: 39902678 PMC: 11791760. DOI: 10.1002/ctm2.70226.

Baricitinib and Pulse Steroids Combination Treatment in Hyperinflammatory COVID-19: A Rheumatological Approach in the Intensive Care Unit.

Ferro F, La Rocca G, Elefante E, Italiano N, Moretti M, Talarico R Int J Mol Sci. 2024; 25(13).

PMID: 39000379 PMC: 11242164. DOI: 10.3390/ijms25137273.

Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress.

Lu X, Peng Q, Wang G Nat Rev Rheumatol. 2023; 20(1):48-62.

PMID: 38057474 DOI: 10.1038/s41584-023-01054-9.

The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review.

Yamamoto S, Yoshida A, Gono T, Kuwana M Curr Rheumatol Rep. 2023; 25(12):264-275.

PMID: 37971581 DOI: 10.1007/s11926-023-01120-x.

Editorial: Advances in understanding the pathogenesis of and designing therapies for connective tissue disease-associated interstitial lung disease.

Duan L, Yang Y, Zhu X Front Immunol. 2023; 14:1295647.

PMID: 37908365 PMC: 10614154. DOI: 10.3389/fimmu.2023.1295647.

References

Carbajo-Lozoya J, Muller M, Kallies S, Thiel V, Drosten C, von Brunn A . Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012; 165(1):112-7. PMC: 7114512. DOI: 10.1016/j.virusres.2012.02.002. View

Li J, Liu Y, Li Y, Li F, Wang K, Pan W . Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis. J Dermatol. 2017; 45(1):46-52. DOI: 10.1111/1346-8138.14092. View

Chen Z, Wang X, Ye S . Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med. 2019; 381(3):291-293. DOI: 10.1056/NEJMc1900045. View

Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T . Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018; 57(12):2114-2119. DOI: 10.1093/rheumatology/key188. View

Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-1034. PMC: 7270045. DOI: 10.1016/S0140-6736(20)30628-0. View

Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A . Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology. 2020; 95(1):e70-e78. PMC: 7371381. DOI: 10.1212/WNL.0000000000009727. View

Nishioka A, Tsunoda S, Abe T, Yoshikawa T, Takata M, Kitano M . Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod Rheumatol. 2018; 29(5):814-820. DOI: 10.1080/14397595.2018.1548918. View

Dias Junior A, Sampaio N, Rehwinkel J . A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. Trends Microbiol. 2018; 27(1):75-85. PMC: 6319154. DOI: 10.1016/j.tim.2018.08.007. View

Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M . Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014; 53(12):2196-203. DOI: 10.1093/rheumatology/keu258. View

10.

Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L . Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020; 146(1):137-146.e3. PMC: 7250105. DOI: 10.1016/j.jaci.2020.05.019. View

11.

Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K . HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011; 105(9):1380-7. DOI: 10.1016/j.rmed.2011.05.006. View

12.

Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H . Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene.... Arthritis Rheumatol. 2019; 72(3):488-498. DOI: 10.1002/art.41105. View

13.

Ledford H . Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020; 582(7813):469. DOI: 10.1038/d41586-020-01824-5. View